Dsm N.v.

Baxter Trading Gmbh

Baxter Aktiengesellschaft

Robert Willem Van Leen

Hans Pannekoek

Albert Johannes Joseph Van Ooyen

Martinus Philippus Verbeet

Gerard Wagemaker

Yvonne Johanna Vos

Lambertus Christiaan Johannes Dorssers

Lambertus Christian Johannes Dorssers

Albert Johannes Van Ooyen

Martinus Phillipus Verbeet

Lambertus Christiaan Dorssers

Biologically active deletion and substitution mutants of hIL-3 are provided. Preferred mutants are those having one or more deletions at the N-terminus (amino acids 1-14) and/or the C-terminus (amino acids 116-133, 120-130 and/or 130-133). Preferred substitution mutants include Cys &rarr;Ala and/or Cys &rarr;Ala , Glu &rarr;Lys and Lys &rarr;Glu . These mutants can be used to formulate pharmaceutical compositions. Also disclosed are antibodies directed against specific epitopes localized between amino acids 29 and 54.

Mutants of human interleukin-3

Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occuring Factor VIII. The polypeptides find use in treatment of Hemophilia A.

Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occuring Pactor VIII. The polypeptides find use in treatment of Hemophilia A.

Proteins with Factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

The invention relates to nucleotide sequences encoding human interleukin-3 (hIL-3) as well as recombinant DNAs, expression cassettes, transformed host cells, and recombinant expression methods comprising such sequences. Additionally, the invention describes proteins having hIL-3 activity, as purified, recombinantly produced, or fusion protein forms of hIL-3, as well as methods of using such proteins to produce antibodies capable of immunospecific reaction with hIL-3.

Molecular cloning and expression of the Pro8 isoform of human IL-3

Growing community of inventors

Nijmegen, Netherlands

Robert Willem Van Leen